Skip to main content

Advertisement

Table 1 Characteristics of the study populationa

From: VZV-specific T-cell levels in patients with rheumatic diseases are reduced and differentially influenced by antirheumatic drugs

  Healthy control subjects Patients with RA Patients with seronegative SpA p Value
Total number of tested samples 39 74 19b
Age, years, mean ± SD 58.6 ± 16.2 60.6 ± 13.0 51.4 ± 11.9 0.04c,d
Female sex, n (%) 22 (56.4) 56 (75.7) 11 (57.9) 0.07e
Leukocyte count median (IQR), cells/μl 7320 (3072) (n = 36) 7800 (4240) (n = 73) 7400 (4200) (n = 19) 0.42f
Lymphocytes median (IQR), % 26.0 (11.1) (n = 28) 23.0 (13.6) (n = 73) 26.0 (10.0) (n = 19) 0.12f
Time since disease onset, years, mean ± SD 8.0 ± 6.4 (n = 67) 7.9 ± 8.8 (n = 19) 0.93g
DAS28, mean ± SD 3.76 ± 1.27 (n = 50) 3.72 ± 1.48 (n = 3) 0.96g
CRP median (IQR), mg/L 1.9 (3.7) (n = 64) 4.3 (14.1) (n = 16) 0.03h
ESR median (IQR), mm/h 13.0 (18.5) (n = 52) 14.0 (18.0) (n = 15) 0.57h
Erosive course, % 40.0 (n = 60) 46.7 (n = 15) 0.77i
History of herpes zoster > 3 months ago, n (%) 0 11 (14.9) 1 (5.3) 0.03e
  1. Abbreviations: CRP C-reactive protein, DAS28 Disease Activity Score 28-joint count, ESR Erythrocyte sedimentation rate, RA Rheumatoid arthritis, SpA Seronegative spondylarthritis
  2. The numbers in parentheses (n) refer to the samples for which the respective information was available
  3. aVZV-IgG negative individuals (3 female RA patients (50, 58, and 77 years of age) and 1 male SpA patient (37 years of age), and one sample of an 80 years old female RA patient with an episode of herpes zoster 1 month before sampling were excluded (their leukocyte counts and clinical characteristics were not different from the remaining patients)
  4. bSixteen patients with psoriatic arthritis, three patients with ankylosing spondylitis
  5. cIn posttest, p < 0.05 only between RA and SpA
  6. dOne-way analysis of variance
  7. eχ2 test
  8. fKruskal-Wallis test
  9. gUnpaired t test
  10. hMann-Whitney U test
  11. iFisher’s exact test